CIM
BLUE

Contrarius Investment Management’s bluebird bio BLUE Stock Holding History

Contrarius Investment Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-60,325
Closed -$1.67M – 50
2023
Q4 		$1.67M Sell
60,325
-5,075
-8% -$309K 0.09% 52
2023
Q3 		$3.98M Buy
+65,400
New +$4.59M 0.22% 44

Other funds holding BLUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Contrarius Investment Management's BLUE Position: Q1 2024 in Review

Contrarius Investment Management sold out of bluebird bio (BLUE) in Q1 2024, closing a stake of 60,325 shares — an estimated $1.67M sold.

Contrarius Investment Management first reported a position in BLUE in Q3 2023 and held it in 2 quarters. The position peaked at $3.98M in Q3 2023. 158 funds tracked by Wall St. Rank hold BLUE as of Q1 2024.

  • Contrarius Investment Management reported no remaining bluebird bio position as of Q1 2024 after selling out during the quarter.
  • Contrarius Investment Management sold 60,325 bluebird bio shares in Q1 2024, an estimated $1.67M.
  • Contrarius Investment Management first reported a position in bluebird bio in Q3 2023 and held it in 2 quarters.
  • Contrarius Investment Management's bluebird bio position peaked at $3.98M in Q3 2023.
  • 158 funds tracked by Wall St. Rank held bluebird bio as of Q1 2024.

Based on Contrarius Investment Management's 13F filing for Q1 2024, filed 10 May 2024.